Guangji Pharmaceutical Co., Ltd.

Announcement on Capital Reduction Due to Repurchase and Cancellation of Restricted Stock

Legal Opinion on the 2025 Annual Shareholders Meeting of Hubei Guangji Pharmaceutical Co., Ltd.

Announcement of Resolutions from the 2025 Annual Shareholders' Meeting

Announcement on the Performance Briefing for the Year 2025 and the First Quarter of 2026

2025 Annual Financial Settlement Report

2025 Annual Work Report of the Board of Directors

Announcement on the Proposed Renewal of the Accounting Firm for 2026

2025 Annual Report of Independent Director (Hong Kui)

2025 Annual Report of Independent Director (Mei Jianming)

2025 Annual Report of Independent Director (Guo Wei)

2025 Environmental, Social and Governance (ESG) Report

Internal Control Audit Report

2025 Internal Control Self-Assessment Report

Announcement on Changes in Accounting Policies

Announcement on the Provision for Asset Impairment in 2025

Independent Financial Advisor Report from Dongfang Caifu Securities Co., Ltd. on the Repurchase and Cancellation of All Remaining Restricted Stocks from the 2021 Incentive Plan by Hubei Guangji Pharmaceutical Co., Ltd.

Legal Opinion from Zhejiang Baishi Cheng Law Firm on the Repurchase and Cancellation of All Remaining Restricted Stocks from the 2021 Incentive Plan by Hubei Guangji Pharmaceutical Co., Ltd.

Verification Opinion of the Compensation and Assessment Committee of the 11th Board of Directors on the Repurchase and Cancellation of All Remaining Restricted Stocks from the 2021 Incentive Plan

Announcement on the Repurchase and Cancellation of All Remaining Restricted Stocks from the 2021 Incentive Plan

Announcement on the Expected Daily Related Transactions for 2026

Announcement on the Company's and Subsidiaries' Application for Comprehensive Credit and External Guarantee Quotas from Banks and Other External Institutions

Notice of the 2025 Annual Shareholders' Meeting

Announcement of the Resolutions of the 17th Meeting of the 11th Board of Directors

Announcement on the Proposal Not to Distribute Profits for 2025

2026 First Quarter Report

Special Explanation on the Elimination of Non-Standard Matters from the Previous Period by the Accounting Firm in 2025

Special Explanation by the Board Audit Committee on the Elimination of Matters Related to the 2024 Non-Standard Audit Opinion

Special Explanation by the Board on the Elimination of Matters Related to the 2024 Non-Standard Audit Opinion

Special Audit Opinion on the Accounting Firm's 2025 Revenue Deduction

Evaluation Report on the Accounting Firm's Performance in 2025

Report of the Board Audit Committee on the Accounting Firm's Supervision Responsibilities

Special Audit Report on the Summary Table of Non-Operating Fund Occupation and Other Related Fund Transactions

Summary Table of Non-Operating Fund Occupation and Other Related Fund Transactions for 2025

Special Report on the Board's Self-Examination of Independent Directors' Independence

2025 Annual Audit Report

2025 Annual Report

Summary of the 2025 Annual Report

Legal Opinion of Hubei Zhongqin Law Firm on the Second Extraordinary Shareholders' Meeting of Hubei Guangji Pharmaceutical Co., Ltd. in 2026

Announcement of the Resolutions of the Second Extraordinary Shareholders' Meeting of 2026

Announcement on Purchasing Liability Insurance for Directors and Senior Management

Announcement on Adjusting the Loan Interest Rate of the Controlling Shareholder and Extending the Related Transactions

Notice on the Second Temporary Shareholders' Meeting of 2026

Announcement of Resolutions from the Sixteenth (Temporary) Meeting of the Eleventh Board of Directors

Announcement on the Completion of Acquisition of Minority Shareholder Equity of a Controlled Subsidiary by a Wholly-Owned Subsidiary and Industrial and Commercial Change